DCXR promotes cell proliferation by promoting the activity of aerobic glycolysis in breast cancer

Abstract

The function of human dicarbonyl/l-xylulose reductase (dcXr) in the pathophysiology of breast cancer is yet to be elucidated. The present study aimed to investigate the function of dcXr in glycolysis and the cell cycle of breast cancer cells with respect to cell proliferation. differential expressed DCXR was identified in The Cancer Genome Atlas (TCGA) database and verified in clinical breast cancer tissue. dcXr silencing and overexpression were induced by rna interference and lentiviral vectors, respectively. cell cycle progression, proliferation and glycolytic activity of breast cancer cells were detected by flow cytometry, Cell Counting Kit-8 assay and chemical methods, respectively. Tumorigenicity was detected using nude mice xenograft models. The expression of DCXR was increased in TCGA breast cancer database and the function of dcXr was enriched in 'glycolysis' and 'cell cycle'. Further analysis using clinical breast cancer samples confirmed upregulation of DCXR. The silencing of dcXr suppressed proliferation and cell cycle progression of breast cancer cells and significantly decreased the capacity for glycolysis, thereby demonstrating the effect of dcXr on the function of breast cancer cells. Similar conclusions were obtained in dcXr overexpressing cells; notably, dcXr overexpression promoted proliferation, cell cycle progression at S phase and glycolysis. 2-deoxy-d-glucose inhibited the effect of dcXr on the proliferation and cell cycle progression of breast cancer cells. The present study revealed that dcXr regulated breast cancer cell cycle progression and proliferation by increasing glycolysis activity and thus may serve as an oncogene for breast cancer.

Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer

“…Characteristics of enrichment in the low-risk group included Tnfa signaling Via NF-kB, inflammatory response, IL6 jak stat3 signaling, and interferon-gamma response (Figure 6A). Glycolysis is an essential condition for the occurrence and development of tumors (7,31). Highrisk samples may present a worse prognosis for BC patients by upregulating the glycolytic pathway.…”